[NFS-02] Neuroscience Frontier Symposium 02

[NFS-02-5] DNA/RNA heteroduplex oligonucleotides for neurological diseases

Takanori Yokota (Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan)

Dr. Yokota graduated from Tokyo Medical and Dental University in 1984, and and studied as a research fellow in Bredesen's lab in Burham Institute and Buck Center for Aging Research (CA, USA) in 1999-2000. He accepted a position as Professor in 2010, and Chairman of Department Neurology and Neurological Science, Tokyo Medical and Dental University. He has been a president of Nucleic Acid Therapeutic Society of Japan since 2018 and BOD member of Oligonucleotide Therapeutic Society (OTS) since 2016. He also started “RENA Therapeutics” and ‘Braizon Therapeuttics’. His group has developed DNA/RNA oligonucleotide (HDO) as a third class of oligonucleotide drug which is highly potent and can regulate extra-hepatic organs including CNS through BBB by systemic administration.